arrow
M

Mario Mandalà

University of Perugia
H指数:78
被引数:4.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial

循环肿瘤DNA指导的高风险II期和III期结肠癌辅助治疗降级或升级:PEGASUS II期试验

2026-09-140
OAAI
Tissue and circulating biomarkers in advanced melanoma patients receiving dabrafenib and trametinib

晚期黑色素瘤患者接受达拉非尼和曲美替尼治疗时的组织及循环生物标志物

2026-09-050
PRE
TPRG-04 ETOP 19-21 USZ-STRIKE: IMMUNOTHERAPY OR TARGETED THERAPY WITH OR WITHOUT STEREOTACTIC RADIOSURGERY FOR PATIENTS WITH BRAIN METASTASES FROM MELANOMA OR NON-SMALL CELL LUNG CANCER

TPRG-04 ETOP 19-21 USZ-STRIKE:针对黑色素瘤或非小细胞肺癌脑转移患者的免疫治疗或靶向治疗,联合或不联合立体定向放射外科

2026-08-070
OA
An updated European Organization for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for Merkel Cell Carcinoma (MCC)

一个更新的欧洲癌症研究与治疗组织(EORTC)关于 Merkel Cell Carcinoma(MCC)哨兵淋巴结病理评估的方案

2026-02-170
PRE
Incidence and risk factors of brain metastases in radically resected melanoma patients: a large international cohort study

根治性切除的黑色素瘤患者脑转移的发生率和危险因素: 一项大型国际队列研究

2026-02-030
OAAI
Evaluation of Sonidegib Cytoreductive Activity in Locally Advanced Basal Cell Carcinoma Treatment: A Delphi Consensus

评估Sonidegib在局部晚期基底细胞癌治疗中的细胞减灭活性:一项Delphi共识

2025-10-210
PRE
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial

新辅助PD-1和LAG-3靶向双特异性抗体与其他免疫检查点抑制剂联合治疗可切除黑色素瘤:随机Ib/II期Morpheus-Melanoma试验

2025-09-240
OAAI
A plain language summary of the preliminary results for encorafenib plus binimetinib and pembrolizumab in adults with BRAF V600-mutant melanoma in the STARBOARD study

STARBOARD研究中,encorafenib联合binimetinib和pembrolizumab治疗BRAF V600突变型黑色素瘤成人的初步结果简明摘要。

2025-05-060
OA
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study

一线encorafenib联合binimetinib和pembrolizumab治疗晚期BRAF V600-mutant黑色素瘤: 随机III期STARBOARD研究的安全导入结果

2024-12-010
PRE
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

EORTC1325/KEYNOTE-054试验中pembrolizumab与安慰剂在III期黑色素瘤中的七年分析

2024-11-012
PRE
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
2024-11-011
OAAI
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)

抗PD-1疗法在儿童和青少年黑色素瘤患者中的疗效(MELCAYA研究)

2024-09-010
PRE
Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial

帕博利珠单抗与安慰剂用于高危III期黑色素瘤完全切除后的治疗:EORTC 1325-MG/Keynote-054 III期双盲试验7年结果

2024-09-010
PRE
Primary analysis of the EORTC 1208 Minitub trial: Prospective registry of sentinel node (SN) positive melanoma patients with minimal SN tumor burden

EORTC 1208 Minitub试验的初步分析:前瞻性登记研究,针对哨兵淋巴结(SN)阳性的黑色素瘤患者且具有最低限度SN肿瘤负荷。

2024-09-010
PRE
Transcriptional features of stage IIT4N0/III colon cancer associated with residual disease and ctDNA status after surgery in the PEGASUS trial

PEGASUS试验中,与术后残留病灶及ctDNA状态相关的II期T4N0/III期结肠癌的转录特征

2024-09-010
PRE
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma

哥伦布7年更新: 在BRAF V600E/K突变型黑色素瘤患者中,恩科非尼加比尼美替尼与维罗非尼或恩科非尼的随机,开放标签,III期试验

2024-06-016
OAAI